These findings indicate the presence of a novel drug resistance pathway independent of CRBN induction and suggest that NCoR2 expression may be a potential biomarker for study of immunomodulatory imide drug refractory disease and could be applied to regulate MYC expression to overcome MDR in cancer cells. This evidence concerns the gene MYC and cancer.